As­traZeneca’s cho­les­terol pill is set for Phase 3, but lags be­hind Mer­ck ri­val

As­traZeneca has great am­bi­tions for its mid-stage oral cho­les­terol drug, be­liev­ing that it could reach peak sales of more than $5 bil­lion. Pos­i­tive da­ta pre­sent­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER